Metronidazole Sanofi

ApprovedSmall molecule

MMargareta Hultin

Metronidazole Sanofi is one of 8 small molecule programs targeting Peri-Implantitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peri-ImplantitisActive, not recruiting

Peri-ImplantitisApproved

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Peri-Implantitis

#DrugCompanyPhaseTrials

Minocin

Peridex

1 3

Azithromcyin

BBin Cao

Approved

1 4

Peridex

DDexcel Pharma Technologies Ltd.

Phase 2

1 5

Metronidazole Sanofi

MMargareta Hultin

Approved

1 6

Minocycline Hcl

OOraPharma

Phase 3

2 7

Flagyl

DDePuy Orthopaedics

Preclinical

2 8

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peri-Implantitis1 trial

Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics

Completed·MMargareta Hultin·Phase 4·NCT02185209·77 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metronidazole Sanofi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metronidazole Sanofi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metronidazole Sanofi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Margareta Hultin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMargareta Hultin

Metronidazole Sanofi

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peri-Implantitis1 trial

References

Drug Info

Quick Facts

Related News